Oxigene Site

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions:

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline

Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye. Oxigene

A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration

OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution The shift to Mateon Therapeutics reflected a broader

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

A key Phase II trial showed that a combination of CA4P and Avastin significantly improved progression-free survival in ovarian cancer patients compared to Avastin alone. Anaplastic Thyroid Cancer

OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer